Zymeworks says first patient dosed in Phase 1 trial of ZW191
The Fly

Zymeworks says first patient dosed in Phase 1 trial of ZW191

Zymeworks (ZYME) announced that the first patient has been dosed in the company’s first-in-human Phase 1 trial to evaluate the safety and tolerability of the investigational therapy ZW191 in the treatment of advanced folate receptor-expressing solid tumors including ovarian, endometrial, and non-small cell lung cancers.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App